Bicalutamide en es it fr

Bicalutamide Brand names, Bicalutamide Analogs

Bicalutamide Brand Names Mixture

  • No information avaliable

Bicalutamide Chemical_Formula


Bicalutamide RX_link

Bicalutamide fda sheet

Bicalutamide FDA

Bicalutamide msds (material safety sheet)

Bicalutamide MSDS

Bicalutamide Synthesis Reference

No information avaliable

Bicalutamide Molecular Weight

430.374 g/mol

Bicalutamide Melting Point

191-193 oC

Bicalutamide H2O Solubility

5 mg/L

Bicalutamide State


Bicalutamide LogP


Bicalutamide Dosage Forms


Bicalutamide Indication

For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.

Bicalutamide Pharmacology

Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Bicalutamide Absorption

Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.

Bicalutamide side effects and Toxicity

No information avaliable

Bicalutamide Patient Information

Patients should be informed that therapy with CASODEX and the LHRH analogue should be initiated concomitantly, and that they should not interrupt or stop taking these medications without consulting their physician. Treatment with CASODEX should be started at the same time as treatment with an LHRH analogue.

Bicalutamide Organisms Affected

Humans and other mammals